Navamedic ASA (FRA:N1A)

Market Cap	30.53M -35.3%
Revenue (ttm)	50.75M +9.7%
Net Income	-2.05M
EPS	-0.10
Shares Out	n/a
PE Ratio	n/a
Forward PE	91.13
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,630
Open	1.195
Previous Close	1.215
Day's Range	1.195 - 1.250
52-Week Range	1.155 - 2.180
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 29, 2026

About Navamedic ASA

Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Norway, Sweden, Denmark, Finland, the Netherlands, and internationally. Its product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. The company offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic and propionic...

• Industry: Medical Distribution
• Sector: Healthcare
• Founded: 2002
• Employees: 38
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: N1A

Financial Performance

In 2025, Navamedic ASA's revenue was 565.36 million, an increase of 6.38% compared to the previous year's 531.44 million. Losses were -23.54 million, 329.1% more than in 2024.

Financial numbers in NOK

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Oct 26, 2026

Data Sources Report a data error